Correlation Between Sinphar Pharmaceutical and Medigen Biotechnology
Can any of the company-specific risk be diversified away by investing in both Sinphar Pharmaceutical and Medigen Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sinphar Pharmaceutical and Medigen Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sinphar Pharmaceutical Co and Medigen Biotechnology, you can compare the effects of market volatilities on Sinphar Pharmaceutical and Medigen Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sinphar Pharmaceutical with a short position of Medigen Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sinphar Pharmaceutical and Medigen Biotechnology.
Diversification Opportunities for Sinphar Pharmaceutical and Medigen Biotechnology
0.58 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Sinphar and Medigen is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Sinphar Pharmaceutical Co and Medigen Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medigen Biotechnology and Sinphar Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sinphar Pharmaceutical Co are associated (or correlated) with Medigen Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medigen Biotechnology has no effect on the direction of Sinphar Pharmaceutical i.e., Sinphar Pharmaceutical and Medigen Biotechnology go up and down completely randomly.
Pair Corralation between Sinphar Pharmaceutical and Medigen Biotechnology
Assuming the 90 days trading horizon Sinphar Pharmaceutical is expected to generate 4.88 times less return on investment than Medigen Biotechnology. But when comparing it to its historical volatility, Sinphar Pharmaceutical Co is 4.35 times less risky than Medigen Biotechnology. It trades about 0.18 of its potential returns per unit of risk. Medigen Biotechnology is currently generating about 0.2 of returns per unit of risk over similar time horizon. If you would invest 3,250 in Medigen Biotechnology on November 8, 2024 and sell it today you would earn a total of 350.00 from holding Medigen Biotechnology or generate 10.77% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Sinphar Pharmaceutical Co vs. Medigen Biotechnology
Performance |
| Timeline |
| Sinphar Pharmaceutical |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Modest
| Medigen Biotechnology |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Sinphar Pharmaceutical and Medigen Biotechnology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Sinphar Pharmaceutical and Medigen Biotechnology
The main advantage of trading using opposite Sinphar Pharmaceutical and Medigen Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sinphar Pharmaceutical position performs unexpectedly, Medigen Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will offset losses from the drop in Medigen Biotechnology's long position.The idea behind Sinphar Pharmaceutical Co and Medigen Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Complementary Tools
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |